Latest News and Press Releases

— Company Granted U.S. Orphan Drug Designation for IPI-926 for the Treatment of Chondrosarcoma — — Rationale for Developing IPI-926 in Chondrosarcoma to be...

CAMBRIDGE, Mass., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011...

CAMBRIDGE, Mass., Feb. 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination...

CAMBRIDGE, Mass., Jan. 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the...

CAMBRIDGE, Mass., Jan. 5, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the J.P. Morgan 29th Annual Healthcare Conference on Thursday, January 13, 2011 at...

CAMBRIDGE, Mass., Jan. 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announces that, effective today, it has been named to the NASDAQ Global Select Market tier, the premier...

Mundipharma Commits to Providing Up to $110 Million in R&D Funding for 2012 in Addition to $85 Million Previously Committed for 2011 Companies Agree Upon Event-Based Approach for IPI-926...

CAMBRIDGE, Mass., Nov. 22, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Piper Jaffray 22nd Annual "Unplugged" Health Care Conference on Wednesday,...

Ongoing Clinical Trial Evaluating a New Approach for Pancreatic Cancer, One of the Most Difficult to Treat Cancers Spotlight on Pancreatic Cancer Awareness Month in November DENVER, Nov. 16,...

–   Ongoing Clinical Trial Evaluating a New Approach for Pancreatic Cancer, One of the Most Difficult to Treat Cancers – –   Spotlight on Pancreatic...